{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:08:14Z","timestamp":1771708094499,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["Grant No. LY14H160045"],"award-info":[{"award-number":["Grant No. LY14H160045"]}]},{"name":"Hangzhou Science and Technology Commission","award":["Grant No. 20140633B41"],"award-info":[{"award-number":["Grant No. 20140633B41"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The majority of patients diagnosed with hepatocellular carcinoma (HCC) have advanced diseases and many are not eligible for curative therapies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We report a rare case of HCC from a patient who had a complete response (CR) with the use of combination of Lenvatinib and Pembrolizumab. A 63-year-old man presented at the hospital with serious abdominal pain and was found to have a mass with heterogeneous enhancement and with hemorrhage in segment III of the liver after the examination of abdominal computerized tomography (CT) scan. The patient\u2019s history of viral hepatitis B infection, liver cirrhosis and the \u0251-fetoprotein (AFP) level of 14,429.3\u2009ng\/ml supported the clinical diagnosis of HCC and laboratory results demonstrated liver function damage status (Child-Pugh class B, Score 8). The patient first received hepatic arterial embolization treatment on 28th November 2017. At this stage supportive care was recommended for poor liver function. In February 2018, combined immunotherapy of Pembrolizumab (2\u2009mg\/kg, q3w) and Lenvatinib (8\u2009mg\u20134\u2009mg, qd) were performed. Nine months following the treatment he had a CR and now, 22\u2009months since the initial treatment, there is no clinical evidence of disease progression. The current overall survival is 22\u2009months.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>HCC is a potentially lethal malignant tumor and the combination of immunotherapy plus anti-angiogenic inhibitors shows promising outcome for advanced diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6287-8","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:51:47Z","timestamp":1573224707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Zhaonan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuequn","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"issue":"1","key":"6287_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"6287_CR2","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/cncr.31551","volume":"124","author":"KA Cronin","year":"2018","unstructured":"Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of Cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785\u2013800.","journal-title":"Cancer"},{"issue":"11","key":"6287_CR3","first-page":"5737","volume":"35","author":"M Stotz","year":"2015","unstructured":"Stotz M, Gerger A, Haybaeck J, Kiesslich T, Bullock MD, Pichler M. Molecular targeted therapies in hepatocellular carcinoma: Past, Present and Future. Anticancer Res. 2015;35(11):5737\u201344.","journal-title":"Anticancer Res"},{"issue":"11","key":"6287_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1634\/theoncologist.2014-0190","volume":"19","author":"S Qin","year":"2014","unstructured":"Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014;19(11):1169\u201378.","journal-title":"Oncologist"},{"issue":"23","key":"6287_CR5","first-page":"2498","volume":"359","author":"DH Palmer","year":"2008","unstructured":"Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(23):2498 author reply 2498-2499.","journal-title":"N Engl J Med"},{"issue":"1","key":"6287_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"1","key":"6287_CR7","doi-asserted-by":"publisher","first-page":"HEP01","DOI":"10.2217\/hep-2017-0020","volume":"5","author":"F Tovoli","year":"2018","unstructured":"Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol. 2018;5(1):HEP01.","journal-title":"Hepat Oncol"},{"issue":"10126","key":"6287_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England). 2018;391(10126):1163\u201373.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"6287_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11864-019-0601-1","volume":"20","author":"K Mody","year":"2019","unstructured":"Mody K, Abou-Alfa GK. Systemic therapy for advanced hepatocellular carcinoma in an evolving landscape. Curr Treat Options in Oncol. 2019;20(2):3.","journal-title":"Curr Treat Options in Oncol"},{"issue":"7","key":"6287_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"10088","key":"6287_CR11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"4","key":"6287_CR12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C. Immunomodulatory effects of current targeted therapies on hepatocellular carcinoma: implication for the future of immunotherapy. Semin Liver Dis. 2018;38(4):379\u201388.","journal-title":"Semin Liver Dis"},{"issue":"Suppl 1","key":"6287_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000481245","volume":"93","author":"M Kudo","year":"2017","unstructured":"Kudo M. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology. 2017;93(Suppl 1):147\u201359.","journal-title":"Oncology"},{"issue":"12","key":"6287_CR14","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993\u20134002.","journal-title":"Cancer Sci"},{"key":"6287_CR15","doi-asserted-by":"crossref","unstructured":"Kato Y , Bao X , Macgrath S, et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Annals of Oncology. 2016, 27(suppl_6).","DOI":"10.1093\/annonc\/mdw362.02"},{"key":"6287_CR16","doi-asserted-by":"crossref","unstructured":"Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019: S1470-2045(19)30020\u20138.","DOI":"10.1016\/S1470-2045(19)30020-8"},{"issue":"5","key":"6287_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4251\/wjgo.v10.i5.108","volume":"10","author":"M Contratto","year":"2018","unstructured":"Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol. 2018;10(5):108\u201314.","journal-title":"World J Gastrointest Oncol"},{"issue":"4_suppl","key":"6287_CR18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1200\/JCO.2017.35.4_suppl.673","volume":"35","author":"Howard S. Hochster","year":"2017","unstructured":"Hochster HS, Bendell JC, Cleary JM, et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35 (suppl 4S; abstract 673).","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"6287_CR19","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2019.37.15_suppl.2522","volume":"37","author":"Shota Fukuoka","year":"2019","unstructured":"Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). ASCO, 2019, ABSTRACT 2522.","journal-title":"Journal of Clinical Oncology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6287-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:15:49Z","timestamp":1604708149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6287-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6287"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6287-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by Ethic Committee of the 903rd Hospital of PLA. The patient and his relations have signed an informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and his family were informed that the information published may potentially compromise anonymity. Publication was consented by the patient. Written informed consent was obtained from the case patient for publication of this report and any accompany images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1062"}}